5:53 PM
 | 
Oct 29, 2013
 |  BC Extra  |  Top Story

Vertex cutting jobs on waning Incivek sales

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported 3Q13 financial results on Tuesday and said it will reduce headcount by 370 (15%) to about 1,800 as a result of the "continued and rapid decline" in sales of its HCV drug Incivek telaprevir. The company -- which has seen Incivek sales fall as doctors and patients wait for all-oral combination therapies --...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >